Antt-tgfbp3 antibodies to treat cancer and sarcopenia

Anti-IGFBP-3 antibodies address the challenge of low survival rates and SMW in PDAC by neutralizing IGFBP-3, restoring IGF-1 signaling, and reducing tumor growth and muscle wasting, offering a dual therapeutic benefit for PDAC patients.

WO2026128221A1PCT designated stage Publication Date: 2026-06-18UNIVERSITY OF ROCHESTER
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
UNIVERSITY OF ROCHESTER
Filing Date
2025-11-25
Publication Date
2026-06-18

Smart Images

  • Figure IMGF000014_0001
    Figure IMGF000014_0001
  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000016_0001
    Figure IMGF000016_0001
Patent Text Reader

Abstract

This application relates to antibodies and methods for treating cancer and sarcopenia. Provided are anti-insulin-like growth factor binding protein-3 (IGFBP-3) antibodies or antigen- binding fragments thereof.
Need to check novelty before this filing date? Find Prior Art